Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma (original) (raw)

“…A feasible prevention strategy for oncology may be targeted B-cell inhibition with anti-CD20 agents, such as rituximab, veltuzumab, or obinutuzumab, which inhibit de novo humoral antibody responses. Several trials have been done with B-cell-inhibiting agents, but these did not detect effects on ADA formation [61,69,72,87,101,102]. Hassan et al showed that rituximab was able to induce full depletion of CD20-positive B cells, but this did not prevent ADAs targeted toward the therapeutic drug [103].…”